Clinical Trials

FORTE is a colorectal cancer prevention study looking to determine how often participants who have had 1-2 small benign polyps removed during colonoscopy from their colon otherwise known as adenomatous polyps or adenomas should have repeat surveillance colonoscopies. The primary goal of FORTE is to compare the colorectal cancer rates between the two study groups (repeat colonoscopy at 5 and 10 years versus repeat colonoscopy at 10 years) to see if the rates are equivalent. If they are equivalent, then people in the future would likely be recommended to only undergo a 10-year exam and the 5-year exam may not be necessary. Participants will be asked to donate blood and stool samples and will be followed annually.

Kidwell, Anna

kidwell.anna@marshfieldresearch.org

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI  54401

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

The primary objective of the study is to prospectively estimate the proportion of NCORP community practices that experience a cancer care delivery problem attributable to a drug shortage of infusional therapeutic oncology drugs. Drug shortages are determined using the Utah Drug Information Service database that identifies drug shortages in real time. Secondary objectives are: To prospectively estimate the rate of cancer care delivery problems (defined above) attributable to a drug shortage of infusional therapeutic oncology drugs for patient populations treated with: a) all cancer drugs, b) all cancer drugs in shortage, and c) each individual cancer drug in shortage. Exploratory objectives are: To assess practice factors (e.g., case mix, size, and practice type) associated with the likelihood that a practice reports cancer care delivery problems. To describe how practice-level strategies in response to drug shortages vary by practice characteristics. To describe the possible effects on clinical trials (e.g., unable to enroll a patient or changing to an alternative treatment). To characterize cancer care delivery problems attributable to a shortage of supportive care agents. To characterize cancer care delivery problems attributable to a shortage of oral anti-cancer agents.

Bulgrin, Angela M

BULGRIN.ANGELA@marshfieldresearch.org

(715) 221-7261

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend the time until the cancer gets worse.

Wilson, Anna E

wilson.anna@marshfieldresearch.org

(715) 858-6860

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

This study examines the side effects that occur from receiving immunotherapy (immune checkpoint inhibitor) in patients with malignant solid tumors. Immunotherapy is the type of treatment that helps your immune system fight cancer. In the future, this information may help participants and their doctors make better decisions about cancer treatments.

Wilson, Anna E

wilson.anna@marshfieldresearch.org

(715) 858-6860

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

This phase II trial tests whether encorafenib and cetuximab with and without nivolumab works to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Encorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for proliferation. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.. Giving encorafenib and cetuximab with nivolumab may be more effective at stopping the growth of new cancer cells in patients with metastatic or unresectable colorectal cancer than encorafenib and cetuximab alone.

Humphrey, Logan J

humphrey.logan@marshfieldresearch.org

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

This phase II trial tests whether cabozantinib with or without atezolizumab works to shrink tumors in patients with papillary kidney cancer that has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with atezolizumab may prevent papillary kidney cancer from growing or spreading compared to cabozantinib alone.

Kidwell, Anna

kidwell.anna@marshfieldresearch.org

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

To compare the proportions of participants in the Tomosynthesis (TM) and Digital Mammography (DM) study arms experiencing the occurrence of an advanced breast cancer at any time during a period of 4.5 years from randomization,including the period of active screening and a period of clinical follow-up after the last screen (T4).

Bello, Tolulope O

bello.tolulope@marshfieldresearch.org

(715) 221-7267

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

This is a prospective cohort study that examines the impact of myopenia on chemotherapy toxicity in overall survival (OS) in older adults with newly diagnosed metastatic colorectal cancer (CRC) receiving 5-Fluouracil (5FU)systemic chemotherapy. The study also explores the mediating influence of genetic variation in the association between myopenia and chemotherapy toxicity.

Craig, Chani L

craig.chani@marshfieldresearch.org

(715) 358-1838

Marshfield Medical Center - Rice Lake

1700 W STOUT ST

RICE LAKE, WI  54868

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI  54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Minocqua

9601 TOWNLINE RD

MINOCQUA, WI  54548

MMC - River Region at Stevens Point

,   

MMC - Weston

3501 CRANBERRY BLVD

WESTON, WI  54476

To determine whether an Internet-based pain coping skills program plus enhanced usual care, compared to enhanced usual care alone, yields significant improvements in the co-primary outcomes of pain severity (as measured by the Brief Pain Inventory (BPI)) and pain interference (also measured by the BPI) from baseline to the post-intervention assessment for cancer survivors with persistent pain.

Humphrey, Logan J

humphrey.logan@marshfieldresearch.org

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449

MMC - Neillsville

216 Sunset Place

Neillsville, Wi  54456

This study evaluates immunologic response following COVID-19 vaccination in children, adolescents, and young adults with cancer. Vaccines work by stimulating the body's immune cells to respond against a specific disease. The immune response produces protection from that disease. Effects from cancer and from treatments for cancer can reduce the body's natural disease fighting ability (called immunity). Factors such as vaccine type, timing of vaccine dosing related to treatment for cancer and number of vaccine doses or boosts (extra vaccine shots) may strengthen or diminish the body's protective immune response. This study may help researchers learn more about how the body's immune system responds to the COVID-19 vaccine when the vaccination is given during or after cancer treatment.

Welter, Stacy L

welter.stacy@marshfieldresearch.org

(715) 221-6492

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI  54449